Brian J. Linder

Brian J. Linder

Auto-generated profile, based on publicly available information

Brian J. Linder

Mayo Clinic Department of OB/Gyn Division of Urogynecology Rochester Minnesota USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
RRRubin Raju
Rubin Raju
BLBrian J. Linder
Brian J. Linder

1 February 2020 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
RRRubin Raju
Rubin Raju
BLBrian J. Linder
Brian J. Linder

1 October 2018 in Journal of Urology
Verified
Journal Article
Closed access
BLBrian J. Linder
Brian J. Linder
JOJohn A. Occhino
John A. Occhino
EHElizabeth B. Habermann
Elizabeth B. Habermann
AGAmy E. Glasgow
Amy E. Glasgow
KBKatherine A. Bews
Katherine A. Bews
BGBoris Gershman
Boris Gershman
We evaluated the perioperative morbidity of open abdominal sacrocolpopexy and minimally invasive sacrocolpopexy using data on a contemporary nationwide cohort. We used the ACS (American College of Surgeons) NSQIP® (National Surgical Quality Improvement Program) database to identify women who underwent abdominal or minimally invasive sacrocolpopexy from 2010 to 2016. Associations of surgical approach with 30-day complications, blood transfusion, prolonged hospitalization and reoperation were evaluated by logistic regression. Hospital readmission within 30 days was calculated by the person-years method and Cox proportional hazard models. A total of 4,362 women underwent sacrocolpopexy, including abdominal sacrocolpopexy in 1,179 (27%) and minimally invasive sacrocolpopexy in 3,183 (73%). The proportion of minimally invasive sacrocolpopexy increased during the study period from 70% in 2010 to 82% in 2016. Baseline characteristics were similar between the treatment groups aside from a higher rate of chronic obstructive pulmonary disease (p = 0.03) and higher preoperative albumin (p <0.0001) among abdominal sacrocolpopexy cases. Compared to abdominal sacrocolpopexy, minimally invasive sacrocolpopexy was associated with lower rates of 30-day complications (p = 0.001), deep vein thrombosis/pulmonary embolism (p = 0.02), surgical site infections (p <0.0001), shorter hospitalization (p <0.0001) and fewer blood transfusions (p = 0.01). Minimally invasive sacrocolpopexy was also associated with a lower 30 person-days readmission rate (2% vs 2.7%, p ≤0.0001) and 30-day reoperation rate (1.1% vs 1.4%, p <0.0001). On multivariable analysis minimally invasive sacrocolpopexy was independently associated with a reduced risk of 30-day complications (OR 0.46, 95% CI 0.28, 0.76, p = 0.002), blood transfusion (OR 0.33, 95% CI 0.15, 0.74, p = 0.007), prolonged hospitalization (OR 0.16, 95% CI 0.12, 0.23, p <0.001) and readmission (HR 0.62, 95% CI 0.41, 0.96, p = 0.03). Minimally invasive sacrocolpopexy was associated with reduced rates of 30-day complications, blood transfusion, prolonged hospitalization and hospital readmission compared to abdominal sacrocolpopexy.

1 December 2016 in International braz j urol
Verified
Journal Article
Open access
PDF file
MWMary E. Westerman
Mary E. Westerman
SBStephen A. Boorjian
Stephen A. Boorjian
BLBrian J. Linder
Brian J. Linder
Keywords: Cystitis; Hematuria; Urinary Bladder; Radiotherapy

21 August 2015 in International Urogynecology Journal
Verified
Journal Article
Closed access
PDF file
BLBrian J. Linder
Brian J. Linder
MAMallika Anand
Mallika Anand
AWAmy L. Weaver
Amy L. Weaver
JWJoshua L. Woelk
Joshua L. Woelk
CKChristopher J. Klingele
Christopher J. Klingele
JGJohn B. Gebhart
John B. Gebhart

1 February 2020 in Translational Andrology and Urology
Verified
Journal Article
Open access
PDF file
TBTimothy C. Boswell
Timothy C. Boswell
DEDaniel S. Elliott
Daniel S. Elliott
LRLaureano J. Rangel
Laureano J. Rangel
BLBrian J. Linder
Brian J. Linder
Background: Artificial urinary sphincter (AUS) placement is the standard for treatment of severe male stress urinary incontinence (SUI). While there is evidence to suggest satisfactory device survival, there is a paucity of data addressing long-term quality of life outcomes. Methods: We identified patients who underwent primary AUS placement from 1983 to 2016. We assessed rates of secondary surgery (overall, device infection/erosion, urethral atrophy, malfunction) and factors associated with these endpoints. Quality of life was evaluated by pad usage and Patient Global Impression of Improvement (PGI-I) at various time points from primary surgery. Follow-up was obtained in clinic or by phoned/mailed correspondence. Results: During the study time frame, 1,154 patients were eligible and included in the analysis. Patients had a median age of 70 years (IQR, 65–75 years) and median follow up of 5.4 years (IQR, 1.6–10.5 years). Overall device survival was 72% at 5 years, 56% at 10 years, 41% at 15 years, and 33% at 20 years. On univariate analysis, variables associated with need for secondary surgery were prior cryotherapy (HR 2.7; 95% CI, 1.6–4.6; P<0.01) or radiation therapy (HR 1.4; 95% CI, 1.1–1.7; P=0.01). On multivariable analysis, only cryotherapy remained significantly associated with this endpoint (HR 2.4; 95% CI, 1.3–4.2; P10 years out from surgery, respectively, reported using a security pad or less per day, 78% and 81% of those patients, respectively, reported their PGI-I as at least “much better”. Conclusions: AUS placement has excellent long-term outcomes, and is associated with sustained improvement in patient quality of life.